Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9426415 | 0.82 | MEN1 (1.00) | MEN1KMT2AKCNH2GAAALDH1A1 | |
| SCHEMBL2927709 | 0.80 | MEN1 (0.73) | MEN1KMT2AKCNH2GAAFAAH | |
| SCHEMBL27552111 | 0.80 | MEN1 (0.73) | MEN1KMT2AKCNH2GAAFAAH | |
| SCHEMBL3608586 | 0.79 | FAAH (0.86) | MEN1KMT2AKCNH2FAAH | |
| SCHEMBL4925003 | 0.79 | HDAC1 (0.75) | KCNH2GAAALDH1A1FAAHHDAC4 | |
| SCHEMBL6474890 | 0.78 | GAA (0.96) | KMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL5524549 | 0.77 | MEN1 (0.69) | MEN1KMT2AKCNH2GAAFAAH | |
| SCHEMBL17275260 | 0.77 | MEN1 (0.69) | MEN1KMT2AKCNH2GAAFAAH | |
| SCHEMBL25238918 | 0.77 | MEN1 (0.89) | MEN1KMT2AKCNH2GAAALDH1A1 | |
| SCHEMBL17512174 | 0.76 | DRD4 (0.76) | MEN1KMT2AKCNH2SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MEN1 4707/4885KMT2A 1156/4885KCNH2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.